TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 EUR)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
1,993,782
|
1,688,488
|
1,518,446 |
Financial expenses |
104,722
|
44,661
|
44,393 |
Earnings before taxes |
266,222
|
298,428
|
322,190 |
EBITDA |
651,947
|
546,984
|
560,580 |
Total assets |
6,671,503
|
4,717,342
|
4,758,138 |
Current assets |
1,141,943
|
1,007,432
|
858,325 |
Current liabilities |
1,720,890
|
1,335,065
|
856,662 |
Equity capital |
3,052,181
|
2,383,563
|
2,268,820 |
- share capital |
17,484
|
15,276
|
16,525 |
Employees (average) |
1,772
|
1,556
|
1,559 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
45.7%
|
50.5%
|
47.7% |
Turnover per employee |
1,125
|
1,085
|
974 |
Profit as a percentage of turnover |
13.4%
|
17.7%
|
21.2% |
Return on assets (ROA) |
5.6%
|
7.3%
|
7.7% |
Current ratio |
66.4%
|
75.5%
|
100.2% |
Return on equity (ROE) |
8.7%
|
12.5%
|
14.2% |
Change turnover |
300,379
|
293,037
|
26,205 |
Change turnover % |
18%
|
21%
|
2% |
Chg. No. of employees |
216
|
-3
|
50 |
Chg. No. of employees % |
14%
|
0%
|
3% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.